0 427

Cited 52 times in

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.

DC FieldValueLanguage
dc.contributor.author김혜련-
dc.contributor.author심효섭-
dc.contributor.author이창영-
dc.contributor.author조병철-
dc.contributor.author차윤진-
dc.date.accessioned2017-02-27T08:15:03Z-
dc.date.available2017-02-27T08:15:03Z-
dc.date.issued2016-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/147129-
dc.description.abstractINTRODUCTION: PD-L1 expression is a predictive biomarker for response to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint inhibitors and can be evaluated by immunohistochemistry. Results of the clinicopathologic characteristics of PD-L1-positive lung adenocarcinoma have been inconsistent in previous studies, and there are no reports on the relationship between PD-L1 expression and p53 status in lung adenocarcinoma. METHODS: We examined PD-L1 and p53 expression in a total of 323 surgically resected lung adenocarcinoma cases using anti-PD-L1 (clone SP142) and anti-p53 (clone DO-7) antibodies, and analyzed the clinicopathologic characteristics of PD-L1-positive cases and their relationship with p53 status. RESULTS: PD-L1 expression in tumor cells was positive in 60 of 323 cases (18.6%). Higher PD-L1 expression (≥50%) was more prevalent in former or current smokers (p=0.026) and was associated with more pack-years (p=0.016). PD-L1-positive tumors were significantly associated with solid predominant type (p<0.001), p53 aberrant expression (p<0.001), and PD-L1 expression in tumor-infiltrating immune cells (p<0.001). Patients with stage I to III tumors harboring PD-L1-positive tumor cells showed poor recurrence-free survival (p<0.001) and overall survival (p<0.001) on univariate analysis. CONCLUSIONS: PD-L1 expression in tumor cells, solid predominant histology, p53 aberrant expression, and PD-L1 expression in tumor-infiltrating immune cells are closely related. These variables should be considered when analyzing the clinical outcomes of patients with lung adenocarcinomas treated with anti-PD1/PD-L1 immune checkpoint inhibitors.-
dc.description.statementOfResponsibilityrestriction-
dc.format.extent73~80-
dc.languageEnglish-
dc.publisherElsevier Scientific Publishers-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/metabolism*-
dc.subject.MESHAdenocarcinoma/mortality-
dc.subject.MESHAdenocarcinoma/pathology*-
dc.subject.MESHAdenocarcinoma/surgery-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHB7-H1 Antigen/metabolism*-
dc.subject.MESHBiomarkers, Tumor/metabolism-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHGenes, erbB-1/genetics-
dc.subject.MESHGenes, p53/immunology*-
dc.subject.MESHHumans-
dc.subject.MESHImmunotherapy-
dc.subject.MESHLung Neoplasms/metabolism*-
dc.subject.MESHLung Neoplasms/mortality-
dc.subject.MESHLung Neoplasms/pathology*-
dc.subject.MESHLung Neoplasms/surgery-
dc.subject.MESHLymphocytes, Tumor-Infiltrating/metabolism-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMolecular Targeted Therapy-
dc.subject.MESHMutation-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHProtein-Tyrosine Kinases/genetics-
dc.subject.MESHProto-Oncogene Proteins/genetics-
dc.subject.MESHProto-Oncogene Proteins p21(ras)/genetics-
dc.subject.MESHReceptor Protein-Tyrosine Kinases/genetics-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSmoking/epidemiology-
dc.titleClinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.-
dc.typeArticle-
dc.publisher.locationIreland-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorYoon Jin Cha-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorChang Young Lee-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorHyo Sup Shim-
dc.identifier.doi10.1016/j.lungcan.2016.05.001-
dc.contributor.localIdA04001-
dc.contributor.localIdA01166-
dc.contributor.localIdA02219-
dc.contributor.localIdA03245-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid27237031-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500216303130-
dc.subject.keywordAdenocarcinoma-
dc.subject.keywordCancer immunotherapy-
dc.subject.keywordLung cancer-
dc.subject.keywordPD-L1-
dc.subject.keywordp53-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNameShim, Hyo Sup-
dc.contributor.alternativeNameLee, Chang Young-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameCha, Yoon Jin-
dc.contributor.affiliatedAuthorCha, Yoon Jin-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorShim, Hyo Sup-
dc.contributor.affiliatedAuthorLee, Chang Young-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.citation.volume97-
dc.citation.startPage73-
dc.citation.endPage80-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.97 : 73-80, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.